SCHEMBL4893161

SCHEMBL4893161

Cc1cc(C(F)(F)F)c2c(N)c(C(=O)N(C)Cc3cccc(C(F)(F)F)c3)sc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.56
LIMK1 P53667 2/20 0.51
MAPT P10636 6/20 0.50
ALDH1A1 P00352 3/20 0.50
NPSR1 Q6W5P4 3/20 0.50
USP2 O75604 2/20 0.50
CASP1 P29466 2/20 0.50
CASP7 P55210 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
USP28 Q96RU2 3/20 0.47
USP25 Q9UHP3 1/20 0.47
KMT2A Q03164 6/20 0.46
POLB P06746 1/20 0.46
MEN1 O00255 5/20 0.45
CRHBP P24387 2/20 0.45
CRHR2 Q13324 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
KDM4E B2RXH2 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898416 0.83 LMNA (0.55) LMNALIMK1MAPTALDH1A1NPSR1
SCHEMBL4890105 0.83 CHRM4 (0.63) LMNAMAPTALDH1A1NPSR1USP2
SCHEMBL4890911 0.81 USP28 (0.66) LMNALIMK1MAPTALDH1A1NPSR1
SCHEMBL429441 0.79 LMNA (0.71) LMNAMAPTALDH1A1NPSR1USP2
SCHEMBL28769980 0.75 CHRM4 (0.68) LMNAMAPTALDH1A1NPSR1USP2
SCHEMBL4896350 0.75 CHRM4 (0.75) LMNALIMK1MAPTALDH1A1NPSR1
SCHEMBL4899387 0.74 ALDH1A1 (0.64) LMNALIMK1MAPTALDH1A1NPSR1
SCHEMBL30968413 0.74 ALDH1A1 (0.64) LMNALIMK1MAPTALDH1A1NPSR1
SCHEMBL4898520 0.73 USP28 (0.72) LMNALIMK1MAPTALDH1A1NPSR1
SCHEMBL4898148 0.73 LMNA (0.59) LMNALIMK1MAPTALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 US claimed
EP-1833834-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2007-09-19 EP claimed
WO-2006068618-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2006-06-29 WO claimed
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 US disclosed
EP-1833834-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006068618-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306107-A1 Compounds FURIN, PCSK9, SLC10A1 LMNA 27/4885LIMK1 1715/4885MAPT 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.